Figure 6

Figure 6

Tumor growth in wild-type mice following Hepa1-6 tumor induction after Dhx15 inhibition. (A) On the left, macroscopic images of tumor size in wild-type AUMscramble ASO (scramble) and AUMsilence ASO (Dhx15 specific)-injected mice 5 weeks after mouse Hepa1-6 hepatoma cells implantation. Yellow circles delimitate primary tumor localization. On the right, the graph shows tumor growth in wild-type AUMsilence ASO (Dhx15-specific) or AUMscramble ASO (scramble)-injected mice. Tumor volume was monitored every 3 days until the end of the study. (B) Immunostaining of intratumoral vessels (blood vessels stained with endomucin, panels a and b, and lymphatic vessels stained with anti-Lyve-1 antibody, panels c and d) in wild-type AUMsilence ASO (Dhx15-specific) or AUMscramble-ASO (scramble)-injected mice. Quantifications of total vascular perimeter and lumen of all intratumoral blood vessels, and percentage of Lyve-1-positive immunostaining are shown in the right graph. Bars represent mean ± SEM, * p < 0.05 vs. wild-type mice (n = 10 animals for each condition). Original magnification: 200×. (C) DHX15 levels in the serum of patients with cirrhosis (n = 35), hepatocellular carcinoma (n = 62), and healthy controls (n = 24).